GLP-1s, PCOS, and weight loss: separating real results from TikTok mythology

What did @lesly.velasquezlima actually say?

The transcript itself is song lyrics, not health commentary. The actual claims live in the caption: 10 years of struggling with inflammation, stubborn weight, and a body "constantly working against me," followed by 45 lbs lost, reduced facial puffiness, and improved skin since starting a GLP-1 journey. The hashtags add context: #pcos, #insulinresistance, and #ozempify signal this is a PCOS-related weight loss story tied to GLP-1 medication use.

To be clear, the creator does not make specific dosing claims, name a drug, or promise these outcomes to anyone else. This is a personal testimonial, not a protocol. That distinction matters when we evaluate what's actually being communicated versus what viewers are likely to take away.

Does the science back this up?

Mostly, yes. The biological story the caption implies, that GLP-1 receptor agonists can reduce inflammation and support weight loss in people with PCOS and insulin resistance, is reasonably well-supported. But the connection between GLP-1 use and visible skin or facial changes is less proven than the caption implies.

On the inflammation front, a 2022 trial by Jensterle et al. in Frontiers in Endocrinology found that semaglutide reduced inflammatory markers including CRP in women with PCOS. A broader meta-analysis by Shi et al. (2022, Obesity Reviews) confirmed GLP-1 agonists reduce systemic low-grade inflammation independent of weight loss, which is clinically meaningful for insulin-resistant patients.

On weight loss, the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide produced roughly 15% body weight reduction on average. Forty-five pounds is plausible, especially over an extended period, though results vary significantly by individual.

The "glowing skin" claim is where the science gets thinner. Reduced insulin resistance can improve hormonal acne and sebum production in PCOS patients (a well-documented connection), but calling it a direct GLP-1 skin benefit overstates the evidence.

What did they get wrong (or right)?

They got the core biology right. PCOS is closely linked to insulin resistance, and insulin resistance drives both weight gain and chronic low-grade inflammation. Using a GLP-1 receptor agonist to address that root mechanism is a clinically sound approach that growing evidence supports.

The facial puffiness reduction is interesting. Chronic inflammation can cause water retention and facial bloating in some patients. Weight loss alone would reduce this, but there is emerging, preliminary evidence that GLP-1s have direct anti-inflammatory effects beyond caloric restriction (Frikke-Schmidt et al., 2023, Obesity). Crediting GLP-1s specifically rather than just weight loss is a modest overreach, but not a harmful one.

What they did not do, and deserve credit for, is claim this works for everyone, prescribe a regimen, or suggest a specific drug. The caption explicitly says "this isn't about perfection." That framing is more responsible than most GLP-1 content on TikTok, where miracle-outcome messaging is standard.

What should you actually know?

If you have PCOS and insulin resistance, GLP-1 receptor agonists are a legitimate, increasingly studied option. They are not approved by the FDA specifically for PCOS, but off-label use in this population is growing and several professional societies have acknowledged the evidence base.

A few things worth knowing before you map someone else's results onto your own expectations:

• Weight loss results vary widely. The STEP trials show averages, not guarantees. Some patients lose far less than 15% body weight.
• Inflammation reduction from GLP-1s is real but not uniform across all inflammatory markers or all patients.
• Skin and facial changes attributed to GLP-1s are mostly downstream of weight loss and hormonal improvement, not a direct drug effect with robust evidence.
• GLP-1 medications require a prescription, proper medical supervision, and monitoring. Supply shortages, compounded versions, and online availability have created a complex and sometimes unsafe access environment.
• PCOS is a heterogeneous condition. Insulin resistance is a major driver for many patients, but not all presentations respond the same way.

Personal testimonials like this one can be genuinely useful for people who feel unseen in traditional medical settings. But 45 lbs and a skin glow are outcomes, not promises, and they belong to one person's specific biology, starting point, and treatment history.